Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Operating Expenses (2019 - 2025)

Burning Rock Biotech has reported Operating Expenses over the past 7 years, most recently at -$15.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 32.63% year-over-year to -$15.8 million; the TTM value through Dec 2025 reached -$64.2 million, up 35.69%, while the annual FY2025 figure was $65.5 million, 33.63% down from the prior year.
  • Operating Expenses for Q4 2025 was -$15.8 million at Burning Rock Biotech, up from -$16.2 million in the prior quarter.
  • Over five years, Operating Expenses peaked at -$15.5 million in Q1 2025 and troughed at -$56.1 million in Q4 2021.
  • A 5-year average of -$34.5 million and a median of -$35.4 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: tumbled 154.52% in 2021 and later surged 48.77% in 2024.
  • Year by year, Operating Expenses stood at -$56.1 million in 2021, then rose by 17.63% to -$46.2 million in 2022, then rose by 25.49% to -$34.4 million in 2023, then skyrocketed by 31.82% to -$23.5 million in 2024, then soared by 32.63% to -$15.8 million in 2025.
  • Business Quant data shows Operating Expenses for BNR at -$15.8 million in Q4 2025, -$16.2 million in Q3 2025, and -$16.7 million in Q2 2025.